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Abstract
Objective: To determine a cost-minimizing option for congenital toxoplasmosis in the United States.
Methodology/Principal Findings: A decision-analytic and cost-minimization model was constructed to compare monthly
maternal serological screening, prenatal treatment, and post-natal follow-up and treatment according to the current French
(Paris) protocol, versus no systematic screening or perinatal treatment. Costs are based on published estimates of lifetime
societal costs of developmental disabilities and current diagnostic and treatment costs. Probabilities are based on published
results and clinical practice in the United States and France. One- and two-way sensitivity analyses are used to evaluate
robustness of results. Universal monthly maternal screening for congenital toxoplasmosis with follow-up and treatment,
following the French protocol, is found to be cost-saving, with savings of $620 per child screened. Results are robust to
changes in test costs, value of statistical life, seroprevalence in women of childbearing age, fetal loss due to amniocentesis,
and to bivariate analysis of test costs and incidence of primary T. gondii infection in pregnancy. Given the parameters in this
model and a maternal screening test cost of $12, screening is cost-saving for rates of congenital infection above 1 per
10,000 live births. If universal testing generates economies of scale in diagnostic tools—lowering test costs to about $2 per
test—universal screening is cost-saving at rates of congenital infection well below the lowest reported rates in the United
States of 1 per 10,000 live births.
Conclusion/Significance: Universal screening according to the French protocol is cost saving for the US population within
broad parameters for costs and probabilities.
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Introduction
Toxoplasma gondii infects between one third and one half of the
world’s population, usually without recognized symptoms. Con-
genital toxoplasmosis (CT), however, transmitted transplacentally
from mother to fetus, can have serious and potentially devastating
effects in virtually all infected, untreated children at varying times
in their lives. CT is not a reportable disease in the United States,
nor is a maternal screening program for toxoplasmosis routinely
offered by most health care providers. It is estimated that between
400 and 4,000 infected children are born each year in the United
States, some of whom suffer severe recurring and progressive
visual symptoms, as well as hearing, motor, and cognitive
impairments, and seizures [1–12].
In France, a nationally mandated detection and treatment
program has reduced rates and severity of congenital infections,
such that severe CT, as seen in the United States, is only rarely
encountered [9,13–22]. The French program requires monthly
serologic screening for congenital toxoplasmosis usually beginning
by the 11
th week of gestation for the duration of pregnancy for all
seronegative at-risk mothers. The question addressed herein is
whether and, if so, under what circumstances, screening for
congenital toxoplasmosis according to the French protocol would
be a cost-saving intervention in the United States. Through the
development of a decision-analytic model, cost estimates for a
‘‘screening’’ strategy and ‘‘no screening’’ strategy are generated
and compared.
Congenital toxoplasmosis is a neglected infection in the United
States, particularly for women with inadequate prenatal care, and
can be a devastating disease in developing, tropical countries
[23,24]. In the United States, incidence is higher in southern areas
with temperate and subtropical climates [25–27]. Oocysts can
persist for up to a year in warm, moist soil, especially in humid
climates. The disease is present in persons of all socioeconomic
groups throughout the United States. Some populations, such as
Pennsylvania Amish, have particularly high seroprevalence in
women of child-bearing age [28,29]. In developing and developed
countries, this infection can be life-threatening and cause
prematurity, destruction of the eye, damage to the brain,
hydrocephalus, microcephalus, and seizures. For example, in Belo
Horizonte, Brazil, one in every 300 babies born has active eye
disease due to T. gondii [23].
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lineages of T. gondii have been described [30,31]. Type II T. gondii
is reported to predominate in France, Poland, and the United
States [31]. In a small series, atypical genetic types of T. gondii are
reported to cause unusually severe eye disease in the United States
[32]. The presence of types I, III, and atypical T. gondii parasites in
South and Central America has been associated with significant
human disease, and very recently distinct atypical, now called
Type IV haplotype, parasites have been found in domestic and
wild animals in the United States in substantial numbers [33–40].
In certain areas of Brazil, Colombia, and Guatemala, T. gondii
strains are atypical rather than the three clonal lineages in Europe
and the United States and are often genetically polymorphic
[41,42]. Migration of people from Central and South America and
travel to and from the United States, with some pregnant women
traveling during gestation, may also contribute to disease in the
United States. The presence of environmental contamination by
oocysts is a common source of infection in temperate climates, and
the migratory patterns of birds that feed on ground where oocysts
are present might account for some of the atypical genetic strains
of T.gondii that have been noted in the United States [43].
Furthermore, the globalization of markets with exchange of food
products between North and South America may result in
consumption of meat, fruits, and vegetables contaminated with
oocysts from types I, III and atypical parasites. It is also postulated
that global warming may lead to an increase in incidence of the
infection in some areas of the world [44].
Background Data Concerning Epidemiology, Pathology,
Transmission, and Clinical Manifestations of Congenital
Toxoplasmosis
Toxoplasmosis is a disease caused by the protozoan parasite
Toxoplasma gondii, whose definitive host is the cat. Prevalence of
toxoplasmosis varies greatly across geographic regions, specifically
in relation to differences in climate, dietary practices, and hygiene.
The most recent reliable estimate of T. gondii seroprevalence in the
United States is derived from the National Health and Nutrition
Examination Survey (NHANES 1999–2004). In that survey, sera
were obtained from a cluster sample of US residents and tested by
the Centers for Disease Control and Prevention (CDC) for T. gondii
antibodies. Of nearly 16,000 persons tested, aged 6–49 years old,
age-adjusted seroprevalence was 10.8%, and among women aged
15–44 years, it was 11% [45]. Thus, 89% of US women remain
susceptible to acute Toxoplasma infection during childbearing years,
and their children are at risk for congenital toxoplasmosis.
Estimates of incidence of congenital toxoplasmosis are derived
primarily from three studies conducted in the United States. In the
1970s, two prospective studies reported rates of congenital
infection to be 10 in 10,000 live births [46,47]. Data from two
surveys in Chicago in the 1980s suggest that incidence of CT was 9
in 10,000 live births [48]. More recently, data from the New
England Regional Newborn Screening Program suggest that
congenital infection was detected in 1 in 10,000 live births [49,50],
using a test similar to one that identifies 50% of infections [51,52].
Extrapolated to the approximately 4 million births in the United
States each year, an estimated 400–4,000 infants are born each
year with congenital toxoplasmosis [25].
In the United States, meat (particularly pork and lamb) has been
identified as an important source of infection, yet the proportion of
infection derived from meat versus gardening, eating raw or
unwashed vegetables, exposure to cat feces, poor hand hygiene,
and other routes that go unrecognized is not known [25].
Epidemiological studies of an outbreak of toxoplasmosis in western
Canada in the 1990s implicated the municipal water supply as the
source of infection [53]. Other water-borne outbreaks also have
been reported [54,55].
Most often, congenital transmission occurs in mothers who
acquire primary infection during gestation, although in rare cases
congenital transmission has occurred due to the reactivation of a
chronic infection in women who are immunocompromised (due to
AIDS or various medical treatments) with subsequent congenital
transmission [56,57]. Clinical evidence suggests that T. gondii may
be present in the placenta for a number of weeks before being
transmitted to the fetus, with an observed range from 4 to 16
weeks [57]. The majority of mothers who acquire acute infection
during pregnancy fail to display any obvious symptoms, although a
minority may present with malaise, low-grade fever, or lymph-
adenopathy [5,56].
Not all mothers who become infected with T. gondii transmit the
infection to the fetus; frequency of vertical transmission increases
with gestational age. Risk of transmission of maternal infection
acquired before conception is virtually zero and transmission rates
remain low for approximately the first 10 weeks. After that, the
rate of transmission increases sharply, resulting in a steeply
increasing incidence of congenital infection, with 2/3 of mothers
transmitting after 30 weeks gestation [57].
While infected pregnant women typically present no symptoms,
congenital infection may cause fetal death or injuries including
vision and hearing deficits, cognitive impairment, or central
nervous system lesions. Congenital T. gondii infections have varied
manifestations, including symptomatic neonatal disease, with
prematurity, rash, thrombocytopenia, illness mimicking out sepsis
(rule out sepsis), jaundice, hepatosplenomegaly, hepatitis, anemia,
leukopenia or leukocytosis, seizures, meningitis, encephalitis,
chorioretinitis or chorioretinal scars, vision loss, intracranial
calcifications, hydrocephalus, and microcephalus. Disease, from
mild to severe, may manifest within one month of birth or not until
childhood or adolescent sequelae from previously undiagnosed
infections become apparent, or may include subclinical infection
[5,6,13].
Author Summary
We constructed a decision-analytic and cost-minimization
model to compare monthly maternal serological screening
for congenital toxoplasmosis, prenatal treatment, and
post-natal follow-up and treatment according to the
current French protocol, versus no systematic screening
or perinatal treatment. Costs are based on published
estimates of lifetime societal costs of developmental
disabilities and current diagnostic and treatment costs.
Probabilities are based on published results and clinical
practice in the United States and France. We use sensitivity
analysis to evaluate robustness of results. We find that
universal monthly maternal screening for congenital
toxoplasmosis with follow-up and treatment, following
the French (Paris) protocol, leads to savings of $620 per
child screened. Results are robust to changes in test costs,
value of statistical life, seroprevalence in women of
childbearing age, fetal loss due to amniocentesis, inci-
dence of primary T. gondii infection during pregnancy, and
to bivariate analysis of test costs and incidence of primary
T. gondii infection. Given the parameters in this model and
a maternal screening test cost of $12, screening is cost-
saving for rates of congenital infection above 1 per 10,000
live births. Universal screening according to the French
protocol is cost saving for the US population within broad
parameters for costs and probabilities.
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acquired in the first or second trimester [13]. Despite higher rates
of transmission of maternal infection to the fetus in the third
trimester, transmission that occurs later in pregnancy generally
results in subclinical infection or milder manifestations of
congenital toxoplasmosis at birth.
Prevention Options
Congenital toxoplasmosis can be prevented only by preventing
maternal infection or by stopping transmission from mother to
fetus. Preconceptional and early pregnancy counseling can help
women avoid personal exposure to T. gondii in undercooked food
or material potentially contaminated by cat excrement. A 1994
study of toxoplasmosis in Belgium found that preconceptional
education was associated with a 63% reduction in the rate of
seroconversion [58]. Other studies, however, have found that
mothers giving birth to congenitally infected infants in the United
States commonly do not recognize risk factors for which education
would have been effective [59].
Blocking transmission from mother to fetus by treating mothers
with acute infection is a second way to prevent fetal infection.
Maternal treatment is effective in blocking transmission in up to
60% of treated mothers [22,60]. If transplacental transmission
occurs, manifestations of fetal infection can be managed and
reduced substantially by diagnosing and treating fetal infection in
utero.
Early diagnosis and treatment of neonates and older children to
treat manifest disease or to attempt to prevent disease progression
is another option. With universal neonatal screening, intervention
to treat neonates and children who present with symptoms has
been found to be cost saving [61].
Some proponents of screening programs advocate universal
screening of neonates, whereas others emphasize treating only
infants who present with symptoms of acute infection, or even not
treating at all in the absence of data from placebo-controlled
randomized clinical trials that demonstrate efficacy [9,14,20,57,
62,63]. In most cases, congenital infection is subclinical at birth,
although sequelae develop over time and may cause damage later
in life. Neonatal screening can be achieved at relatively low cost by
expanding established newborn screening programs to include
tests for toxoplasmosis [49,64]. The clear disadvantage of neonatal
screening is that it cannot prevent injury sustained before birth,
which may be permanent and profound.
Universal Prenatal Screening. In some countries, including
Austria, France, and Belgium, systematic prenatal screening for
toxoplasmosis is mandated by law to facilitate early detection of
recently acquired infection in pregnant women. Screening
provides medical benefits of early treatment [6,9], but arguments
against screening include factors such as cost, demographic
characteristics, availability of appropriate tests, and the low
incidence of acute infection.
Clinical or epidemiological grounds are not sufficient to
establish when serologic testing is needed because infection often
occurs in asymptomatic pregnant women with no knowledge of
direct exposure [59]. Maternal serological testing relies on the
detection and quantification of T. gondii antibodies to determine
whether a pregnant woman is infected with toxoplasmosis and
whether the infection was acquired recently. If testing indicates
that infection occurred during gestation or shortly before
conception, the fetus is at risk. Initial screening at clinical
laboratories involves serological testing for IgG (immunoglobulin
G) and, if IgG is positive, for IgM (immunoglobulin M) antibodies.
Women who test negative for T. gondii infection continue to be at
risk of acquiring acute infection and are tested monthly. In the
event of a positive test result before the 11
th week of gestation,
reference laboratories are able to confirm a positive IgM test
result, and using the avidity method and Toxoplasma serological
profile (TSP) to determine whether infection occurred before or
after conception, and thus decrease the need for follow-up samples
and unnecessary additional testing and/or treatment [56]. After
18 weeks, fetal infection can be confirmed through the use of PCR
(polymerase chain reaction) of amniotic fluid [56] with greater
than 92% sensitivity and 100% specificity [65].
Treatment. Treatment of congenital toxoplasmosis has been
shown to reduce severity of symptoms of active infection and to
improve outcomes [5,6,12]. Early diagnosis and treatment
minimizes the time for tissue destruction by the parasite.
Accordingly, favorable outcomes are associated with treating
congenital infection during gestation and infancy [9]. A
prospective study in 14 European centers found that prenatal
treatment reduced the risk of serious neurological sequelae of CT
with an odds ratio for prenatal treatment of 0.24, adjusted for
gestational age at maternal seroconversion [19,21]. There is
significant reduction in sight-threatening retinal disease associated
with more rapid introduction of treatment [16,17].
In France, upon confirmation of acute maternal infection early
in gestation, treatment with spiramycin is initiated immediately.
Spiramycin does not cross the placenta to the fetus, but is present
in high concentrations in the placenta [60], and thus it has been
reported to decrease the frequency of vertical transmission, with
estimates of the reduction of congenital infection of as much as
60% [22,60]. Studies suggest that spiramycin is most efficacious if
administered shortly after maternal seroconversion, and it remains
the recommended treatment option for maternal infection
acquired before 18 weeks of gestation.
Treatment with pyrimethamine, sulfadiazine, and folinic acid
(PSF) is recommended for patients for whom fetal infection has
been confirmed, including when infection is acquired after 18
weeks of gestation, due to the high rates of vertical transmission in
the second and third trimesters [56]. PSF is used to treat infection
in the fetus directly, and studies indicate that treatment with PSF
may markedly reduce disease severity at birth and lifetime
sequelae [14,16–18,20,21,56,66].
Systematic Screening in France. A universal monthly
screening program for congenital toxoplasmosis mandated in
France since 1992 provides the template upon which the model
hereinisbased.In the1960s,seroprevalence ofT.gondiiwas found to
be 84% in France. Although seroprevalence decreased to 54% in
1995 and further to 44% in 2004, rates of T. gondii infection in
France are relatively high compared to the United States and
northern Europe [67]. The reasons for the decrease in
seroprevalence in France are not fully documented but may
include better maternal education for prevention and increased
awareness of the risks of undercooked food in the population as a
whole [68]. A 1984 study found the prevalence of congenital
toxoplasmosis in France to be between 1.9 and 3.2 cases per 1,000
live births [69]. Treatment during gestation to prevent congenital
toxoplasmosis in France involved administration of spiramycin and
PSF (in the manner described earlier). The introduction of treatment
with spiramycin was coincident with an observed 50% reduction in
the incidence of fetal infection in each trimester from decades prior
to initiation of the treatment protocol [14,15,17,22,66,70,71].
Furthermore, due to the delay in transplacental transmission
caused by spiramycin treatment, disease severity at birth was
lessened for infection acquired in each trimester [72]. Treatment
with PSF was similarly effective at reducing disease severity at birth
and subsequent sequelae [14,66].
Congenital Toxoplasmosis Screening
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a national laboratory surveillance system found the overall
prevalence of congenital toxoplasmosis in France in 2007 to be
2.9 to 3.2 per 10,000 live births, and incidence of symptomatic
congenital infection of 0.34 per 10,000 live births [67]. There has
been an 87% decline in the rate of congenital infection in France
since the 1970s, although it is difficult to distinguish between the
effect of the reduction in seroprevalence by nearly 50% and the
effectiveness of education versus treatment. Additionally, elected
pregnancy terminations, which were more common in the early
years of France’s screening program, account for some of the
observed reduction in rates of congenital infection, but they are
now very rare. Nevertheless, the screening program in France has
eliminated or reduced the severity of virtually all clinically
significant, adverse consequences due to congenital toxoplasmosis
[9,17,19,73].
Methods
To determine whether a universal screening program for
congenital toxoplasmosis might be cost saving in the United States,
a decision-analytic model using TreeAge Pro Suite 2011 software
(TreeAge Software, Inc., Williamstown, MA, USA) was devel-
oped, following a methodology used by Douglas Scott and
colleagues at the US Centers for Disease Control and Prevention
in Atlanta, Georgia [61] and by others to evaluate a newborn
screening program [74–76]. The scope of the present study
encompasses the lifetime consequences of congenital toxoplasmosis
in the United States. The recipient population includes mothers
and children screened and treated for congenital toxoplasmosis.
Screening takes place in hospitals and clinical offices, while
confirmation of any positive test result is performed at specialist
reference laboratories with high standards of accuracy, such as the
Toxoplasma Serology Laboratory at Palo Alto, California. The
options considered are: (1) no systematic maternal screening and
(2) universal maternal screening. The consequences of each option
are limited to the various possible medical outcomes, relating to
disease severity and treatment efficacy.
The decision model is structured to reflect the treatment
protocol employed in the French (Parisian) congenital toxoplas-
mosis prevention program and the recommended approach for the
management of toxoplasmosis during pregnancy [9,56]. Accord-
ingly, contrary decisions after the initial choice of option are not
incorporated into the decision model because it is assumed that
doctors will manage cases of congenital toxoplasmosis according to
the recommended protocol.
The ‘‘no maternal screening’’ option assumes that no systematic
screening is performed during pregnancy. Some doctors may
recommend screening, generally if the mother lives with a cat.
Cat-owning, however, is only one environmental risk for maternal
infection. In the ‘‘no screening’’ arm, children who present with
clinical congenital toxoplasmosis at birth are treated in the manner
prescribed to the extent that their symptoms are accurately and
promptly recognized. Outcomes in the no-screening arm include
unrecognized disease, misdiagnosis, delayed diagnosis, delayed
treatment, and consequent irreversible damage at birth or later for
some children.
Probabilities of Maternal Infection, Fetal Infection,
Degree of Disease, and Other Variables
A full listing of probabilities and references is given in Table 1.
The probabilities representing the efficacy of treatment at
reducing adverse disease outcomes were derived primarily from
Parisian data gathered at the reference center in Paris, France
[15–22]. The percentages of children with disease manifestations
reflect lifetime symptoms, not solely those that present at birth and
are derived from clinical data and published studies [13,57,69,77–
80]. Probabilities reflecting prevalence of toxoplasmosis, primary
infection in pregnancy, and incidence of CT in the United States
were extrapolated from national and regional studies within the
United States [45–50]. Additional documentation of the proba-
bilities is contained in the file, Text S1, Supporting Information for
Decision Tree and Table of Probabilities, available on line.
Estimates of Costs of Injury
The perspective of the study is that of societal costs. Cost
estimates, the payoffs in the decision tree framework, were derived
from Research Triangle Institute’s (RTI) report, The Cost of
Developmental Disabilities [81]. The study used the cost-of-illness
(COI) approach to assess the lifetime costs of five developmental
disabilities (DD), three of which are relevant to congenital
toxoplasmosis: severe cognitive impairment, hearing impairment,
and visual impairment. By estimating social costs, the value of all
resources used or lost as a result of the DD is included in the
economic analysis, such as the costs of the medical and
nonmedical services and equipment used as a result of the DD,
as well as the earning and productivity losses for the infected
persons and families who take time to care for the individual with a
DD. The costs are incidence-based estimates, which measure the
lifetime costs for an individual from the onset of the DD to death.
Such estimates attempt to proxy potential cost savings that can be
achieved through treatment to prevent or mitigate injury. Table 2
gives the cost estimates for various outcomes of congenital
infection, with costs discounted at 3%, which is the recommended
discount rate for health interventions used by the World Bank and
the World Health Organization in the Global Burden of Disease
reports [82–84].
We include cost estimates for severe disease requiring home
care, while mild disease does not require home care. For outcomes
characterized by multiple disabilities of a mild nature, specific DD
costs were summed to produce the cost estimate. For outcomes
characterized by multiple disabilities of a severe nature, the cost
estimate for severe cognitive damage was summed with the cost
estimate(s) for the other individual disabilities without home care
costs, to avoid double counting. Costs were calculated based on
normal life expectancy of 76 years and adjusted for impairment-
specific survival probabilities [81]. The outcomes of congenital
toxoplasmosis listed in Table 2 were selected based on observed
clinical outcomes, as confirmed through the medical literature
[13,57,69,77–80] and personal clinical experience (RM).
Indirect costs of psychological impacts borne by family
members were not included in the estimates, nor were the costs
associated with institutionalization in long-term care facilities.
Mild cases are likely to have been underreported [81]. In sum, the
assumptions made and limitations in the data are likely to bias the
cost estimates downward, yielding a lower-bound estimate of the
costs of each DD. Accordingly, the savings associated with
prevention or mitigation of each disease outcome are likely to be
higher than our estimates. We based the cost of fetal death on the
range of estimates for the value of statistical life in the literature
($5,000,000) adjusted to October 2010 dollars [85–89]. This value
is assigned to all fetal death outcomes, regardless of direct cause
(disease or amniocentesis).
Estimates of Screening and Treatment Costs
Total cost estimates of each disease outcome also include test
and treatment costs incurred throughout gestation and one year of
postnatal treatment, as shown in Table 3. At current volumes,
Congenital Toxoplasmosis Screening
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Phase Variable Point est. (range) Reference(s)
No Screening Prob primary infection in pregnancy 0.0011 (0.0004-0.0018) [25,26,45,50,57,68,101]
Prob fetal infection 0.50 [13,57,69,77–79]
Prob fetal death due to CT 0.05 [80]
Prob no fetal disease 0.06 [57,69,77]
Prob visual impairment 0.48 [57,69]
Of which mild 0.09 [57,69]
Prob visual and cognitive impairment 0.45 (0.40-0.55) [57,69,77]
Of which mild 0.39 (0.33-0.45) [57,69,77]
Prob visual, cognitive, hearing impairment 0.01 [57,69,77]
12 Weeks Prob IgG(+) (maternal seroprevalence) 0.11 [26,48,50,68,101]
Prob IgG(+) IgM(+) 0.0011 (0.0004-0.0018) [26,48,50,68,101]
Prob IgG(+) IgM(+) on confirmation 0.9 [26,48,50,68,101]
Prob fetal death due to CT 0.02 [80]
Prob fetal death due to amniocentesis 0.0025 (0.0006-0.0033) [90,92]
Prob amniocentesis (–) 0.9635 [57,67,69,78]
Prob amniocentesis (+) 0.034 [57,67,69,78]
Prob no disease 0.6 [15–22,102]
Prob visual impairment 0.3 (0.10-0.40) [15–22,102]
Prob visual and cognitive impairment 0.095 [15–22,102]
Prob visual, cognitive, hearing impairment 0.005 [15–22,102]
16 Weeks Prob IgG(+) (primary infection in pregnancy) 0.0011 (0.0004-0.0018) [26,48,50,68,101]
Prob IgG(+) IgM(+) on confirmation 0.9 [26,48,50,68,101,103]
Prob fetal death due to amniocentesis 0.0025 [90,92]
Prob amniocentesis (–) 0.9045 [57,69,73]
Prob amniocentesis (+) 0.093 [57,69]
Prob no disease 0.85 [15–22,102]
Prob visual impairment 0.10 [15–22,102]
Prob visual and cognitive impairment 0.025 [15–22,102]
Prob visual, cognitive, hearing impairment 0.025 [15–22,102]
20 Weeks Prob IgG(+) (primary infection in pregnancy) 0.0011 (0.0004-0.0018) [26,48,50,68,101]
Prob IgG(+) IgM(+) on confirmation 0.9 [26,48,50,68,101,103]
Prob fetal death due to amniocentesis 0.0025 [90,92]
Prob amniocentesis (–) 0.8275 [57,69,73]
Prob amniocentesis (+) 0.17 [57,69]
Prob no disease 0.85 [15–22,102]
Prob visual impairment 0.10 [15–22,102]
Prob visual and cognitive impairment 0.025 [15–22,102]
Prob visual, cognitive, hearing impairment 0.025 [15–22,102]
24 Weeks Prob IgG(+) (primary infection in pregnancy) 0.0011 (0.0004-0.0018) [26,48,50,68,101]
Prob IgG(+) IgM(+) on confirmation 0.9 [26,48,50,68,101,103]
Prob fetal death due to amniocentesis 0.0025 [90,92]
Prob amniocentesis (–) 0.7575 [57,69,73]
Prob amniocentesis (+) 0.24 [57,69]
Prob no disease 0.85 [15–22,102]
Prob visual impairment 0.10 [15–22,102]
Prob visual and cognitive impairment 0.025 [15–22,102]
Prob visual, cognitive, hearing impairment 0.025 [15–22,102]
28 Weeks Prob IgG(+) (primary infection in pregnancy) 0.0011 (0.0004-0.0018) [26,48,50,68,101]
Prob IgG(+) IgM(+) on confirmation 0.9 [26,48,50,68,101,103]
Prob fetal death due to amniocentesis 0.0025 [90,92]
Congenital Toxoplasmosis Screening
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$12 per test. The Toxoplasmosis panel at a reference lab for
confirmation of recent infection costs $385 (PAMF-TSL, http://
www.pamf.org/serology). Amniocentesis is assigned a cost of
$1300 per procedure (Personal communication to RM, M.Christ-
mas M.D., Little Company of Mary Hospital, Chicago, 2011).
The total dollar values for test costs included in each cost estimate
reflect the cost per test multiplied by the number of tests required
throughout pregnancy.
Spiramycin is currently not commercially available in the
United States. It can be obtained at no cost after consultation with
the US Food and Drug Administration through a program with
the pharmaceutical company, Sanofi-Aventis; the marginal cost
to the firm is negligible because the drug is produced for other
uses.
Pyrimethamine, sulfadiazine, and folinic acid are used to treat
fetal infection directly for the duration of pregnancy starting after
the 18
th week. At current output, pyrimethamine costs $1.56 per
day and sulfadiazine costs $12.48 per day. Folinic acid costs $0.70
per week in parenteral formula administered orally. Treatment
with PSF continues for approximately one year after birth, and
costs for medicines total $210 for the entire year plus compound-
ing cost of $20 to $50 per week (the lower value of $20 was used).
In addition, there are twice-weekly complete blood counts for the
mother for the duration of pregnancy and for the baby for the first
year of life, at $10 per sample (ipharma.com, 2011).
Total costs for each possible outcome are observable on the
decision tree, Figures 1 and 2, which represent one tree divided to
make it readable. Total cost estimates, reflecting test and
treatment costs as well as estimated costs of disease, appear at
each terminal node (denoted by a triangle), shown as formulae for
the sum of each type of cost times its respective repetitions. As an
example, a child born with mild visual impairment whose mother
was tested at 12 weeks of gestation with a positive result and who
Phase Variable Point est. (range) Reference(s)
Prob amniocentesis (–) 0.7275 [57,69,73]
Prob amniocentesis (+) 0.27 [57,69]
Prob no disease 0.94 [15–22,102]
Prob visual impairment 0.05 [15–22,102]
Prob visual and cognitive impairment 0.005 [15–22,102]
Prob visual, cognitive, hearing impairment 0.005 [15–22,102]
32 Weeks Prob IgG(+) (primary infection in pregnancy) 0.0011 (0.0004-0.0018) [26,48,50,68,101]
Prob IgG(+) IgM(+) on confirmation 0.9 [26,48,50,68,101,103]
Prob fetal death due to amniocentesis 0.0025 [90,92]
Prob amniocentesis (–) 0.3775 [57,69,73]
Prob amniocentesis (+) 0.62 [57,69]
Prob no disease 0.94 [15–22,102]
Prob visual impairment 0.05 [15–22,102]
Prob visual and cognitive impairment 0.005 [15–22,102]
Prob visual, cognitive, hearing impairment 0.005 [15–22,102]
36 Weeks Prob IgG(+) (primary infection in pregnancy) 0.0011 (0.0004-0.0018) [26,48,50,68,101]
Prob IgG(+) IgM(+) on confirmation 0.9 [26,48,50,68,101,103]
Prob no disease 0.94 [15–22,102]
Prob visual impairment 0.05 [15–22,102]
Prob visual and cognitive impairment 0.005 [15–22,102]
Prob visual, cognitive, hearing impairment 0.005 [15–22,102]
Newborn Prob newborn test (+) 0.00055 (0.0002-0.0009) [26,48,50,68,101]
Prob IgG(+) IgM(+) on confirmation 0.9 [26,48,50,68,101,103]
Prob no disease 0.94 [15–22,102]
Prob visual impairment 0.05 [15–22,102]
Prob visual and cognitive impairment 0.005 [15–22,102]
Prob visual, cognitive, hearing impairment 0.005 [15–22,102]
Postnatal Prob postnatal test(+) 0.00055 (0.0002-0.0009) [26,48,50,68,101]
Prob IgG(+) IgM(+) on confirmation 0.9 [26,48,50,68,101,103]
Prob no disease 0.94 [15–22,102]
Prob visual impairment 0.05 [15–22,102]
Prob visual and cognitive impairment 0.005 [15–22,102]
Prob visual, cognitive, hearing impairment 0.005 [15–22,102]
doi:10.1371/journal.pntd.0001333.t001
Table 1. Cont.
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www.plosntds.org 6 September 2011 | Volume 5 | Issue 9 | e1333transmitted to the fetus, in spite of spiramycin treatment, and was
treated with PSF will entail costs as follows:
2 maternal tests + confirmatory test (Toxo panel at a reference
lab) + amniocentesis + spiramycin (free) + PSF for 22 weeks (full
term minus minimum age for PSF of 18 weeks) + 22 weeks of
twice-weekly blood tests for mother + pediatric treatment for 52
weeks (including blood tests and compounding costs) + societal
costs of mild visual impairment. Figures 3 and 4 show the total
costs for each scenario in dollars and the probability of each
outcome, as well as the optimal (cost-minimizing) path.
Sensitivity Analysis
To determine the robustness of results to key parameters,
sensitivity analysis was performed on incidence of primary T. gondii
infection during pregnancy, population seroprevalence, risk of
amniocentesis, the value of statistical life, and test costs because
those variables would have the largest effect on model outcomes.
Moreover, they are the variables most likely to vary between
populations and thus warrant attention in applying the model to
different populations. Net cost is particularly sensitive to
seroprevalence because in populations with very low prevalence
more mothers must be tested repeatedly throughout pregnancy.
Similarly, the societal cost of CT is sensitive in low-incidence
populations. The ranges for prevalence and incidence of primary
infection during pregnancy were derived from estimates for the
United States and regional surveys [13,57,69,77–80].
Risk of fetal death from amniocentesis could have a significant
impact on societal cost because the full value of statistical life is
applied to fetal death. The range for risk of amniocentesis is
derived from high and low estimates from CDC and other
published sources [90–92]. The range for value of statistical life
was derived from a search of estimates in the literature [86,93].
Especially in low-prevalence populations, test costs could have a
large impact on total cost. The upper bound derives from actual
costs, and the lower bound is based on the cost of point-of-service
tests for other conditions because most of the cost for testing is
shipping and administrative expense.
Severity of untreated infection seems to vary between
populations, suggesting that the South American strain is more
virulent than the European strain [27]. Efficacy of treatment,
however, appears to be similar between populations [94]. For the
US population, therefore, sensitivity analysis is not warranted for
efficacy, the value of which is established in the literature [14,16–
18,20,21,56,66].
Results and Discussion
Our results indicate that universal screening is cost saving at an
expected cost of $390 per child screened, inclusive of societal cost
of remaining DD, compared to an expected societal cost of
congenital toxoplasmosis of $1010 per birth under the ‘‘no
maternal screening’’ alternative. Thus, cost savings of $620 per
child are predicted with the implementation of a universal
maternal screening program in the US population with an
estimated 4 million births per year, or nearly $2.5 billion saved
annually compared to no maternal screening. Accordingly, the
initial model suggests a policy recommendation on the basis of cost
savings in favor of a universal maternal screening program for
congenital toxoplasmosis following that currently employed in
France. The results were robust to changing the discount rate to
5%, although the expected saving was reduced to $371 per child
screened. Eliminating amniocentesis at 32 weeks had no significant
effect on the results.
Sensitivity Analysis
One-way sensitivity analysis graphs appear in Figures 5, 6, 7,
and 8. The two lines on each graph correspond to the relevant
decision (screening versus no screening), and any deviation from
horizontal reflects that strategy’s sensitivity to the variable under
consideration. In our model, only differences in the incidence of
primary infection during pregnancy produce a change in the
optimal strategy, which occurs below the lower bound of estimates
for the United States. As seen in Figure 5 (enlarged in Figure 6),
for rates of primary infection during pregnancy of less than 0.0002,
universal screening becomes the non-optimal strategy. Maternal
incidence of 0.0002 corresponds to incidence of congenital
infection on average of 0.0001 (1 in 10,000), based on the 0.50
probability of maternal transmission (over all trimesters) without
treatment [13,57,69,77–79]. As a result, in populations with
extremely low rates of congenital infection, maternal screening is
not found to be cost-saving. For other reasons, one might conclude
that screening is the correct decision, but that determination is
beyond the focus of this study.
Table 2. Cost estimates for outcomes of congenital
toxoplasmosis (RTI estimates adjusted to 2010$).
Developmental Disorder Costs (2010$) at 3% Discount Rate
Fetal Death (any cause) $6,957,043
Visual, mild $537,187
Visual, severe $962,003
Cognitive, mild $1,109,776
Cognitive, severe $2,732,816
Hearing, mild $383,635
Visual + Cognitive, mild $1,646,963
Visual + Cognitive, severe $2,910,003
Visual + Cognitive + Hearing, mild $2,030,598
Visual + Cognitive + Hearing, severe $3,293,638
Based on costs in Honeycutt A, Dunlap, L., Chen, H., al Homsi, G. (2000) The Cost
of Developmental Disabilities: Task Order No. 0621-09. Research Triangle
Institute [81] and US Bureau of Labor Statistics (http://data.bls.gov/cgi-bin/
cpicalc.pl).
doi:10.1371/journal.pntd.0001333.t002
Table 3. Test costs.
Category Test Cost
Screening Serological test for IgG, IgM $12.00
Toxoplasmosis serological profile (TSP) $385.00
Amniocentesis (PCR) $1,300.00
Blood Work Complete blood count $10.00
Treatment Spiramycin $0.00
Pyrimethamine $1.56 per day
Sulfadiazine $12.48 per day
Folinic Acid $0.10 per day
One-year pediatric PSF treatment $210.00
Drug compounding $20.00 per week
Source: (http://www.ipharma.com, 2011).
doi:10.1371/journal.pntd.0001333.t003
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of values reveals that the screening strategy is sensitive to those
assumptions, but no threshold values are reached (Figures 7 and 8,
and other analyses not shown). The expected value for cost of
prenatal screening is less than the expected value for the cost of the
no-screening option for all values of the variables tested. Cost
savings increase with population seroprevalence (Figure 7) since
populations with higher rates of T. gondii infection, over a broad
range, have higher rates of seroconversion over childbearing years
and thus higher benefits (lower societal cost of injury) from
screening. High-prevalence populations also have a smaller pool of
susceptible women and thus will have lower cost of testing.
Conversely, cost savings from universal screening decline with
increasing fetal loss rates due to amniocentesis, with increasing
serological test costs (Figure 8), and with cost of amniocentesis, but
screening remains dominant. Lastly, variation of the value of
statistical life from $600,000 to $10,000,000 had an equal effect on
both the screening and no screening strategies.
Two-way sensitivity analysis was performed on the variables for
test costs and the rate of primary infection during pregnancy.
Figures 9 and 10 reveal that reducing test costs effectively lowers
the rate of primary infection in pregnancy for which screening is
Figure 1. Decision tree with formulae (top).
doi:10.1371/journal.pntd.0001333.g001
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roughly $2 per test, which is feasible given the cost of other in-
office diagnostic tests), screening becomes the optimal strategy
even at rates of primary infection in pregnancy well below the
lowest reported rates of 2 in 10,000 in the United States.
Discussion
The decision-analytic model developed in this paper reveals that
for populations with rates of congenital toxoplasmosis greater than
0.0001 (1 infected child per 10,000 live births, or 2 infected
mothers per 10,000), maternal serological screening is a cost-
saving strategy. This finding is robust to changes in seropreva-
lence, incidence of maternal primary infection, amniocentesis risk,
value of statistical life, and test costs. Given current estimates of the
rate of congenital infection in the United States, implementation of
a universal screening program for congenital toxoplasmosis
prevention and treatment is predicted to generate cost savings of
approximately $620 per birth.
Sensitivity analysis shows that even for populations with
extremely low rates of congenital infection, screening is cost
saving at a test cost of $12 plus confirmatory test at $385.
Nevertheless, policy makers must be cautious when considering
estimates of rates of congenital infection. Some studies have found
rates of congenital infection in the United States below 0.0001
[49,50], casting doubt on cost saving by universal screening as an
intervention strategy at current test costs, although with our
Figure 2. Decision tree with formulae (bottom).
doi:10.1371/journal.pntd.0001333.g002
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doi:10.1371/journal.pntd.0001333.g003
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based on the midpoint of estimates from available sources,
screening is a cost-saving strategy.
Furthermore, if screening is initiated, we expect to observe
economies of scale in test production. If test costs are reduced,
screening becomes cost saving even in populations with rates of
congenital infection below 0.0001. Accordingly, as universal
screening is enacted and test production expanded, economies of
scale in test production may render screening a cost-saving
strategy for all populations, even at extremely low rates of
congenital infection. The capacity to test for several congenital
conditions while drawing blood at one time opens the possibility of
other cost savings (economies of scope). Pooling the costs of testing
for congenital cytomegalovirus and other conditions, for example,
would reduce the threshold for cost savings for all conditions.
The cost-minimization analysis described herein demonstrates
that a careful and robust gestational screening program as carried
out in France can be a cost-saving intervention in the United
Figure 4. Decision tree with monetary values for costs and optimal path (bottom).
doi:10.1371/journal.pntd.0001333.g004
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for preventing toxoplasmosis in developing countries worldwide.
In Brazil, for example, carefully performed and detailed regional
programs are collecting data concerning gestational infection and
congenital toxoplasmosis, which are amenable to analysis with the
paradigm developed herein [27]. This paradigm is also readily
applicable to analyses of other neglected tropical diseases.
Limitations
The recommendation of screening is complicated by the
disparity between a best practice scenario, such as that analyzed
in this study, and US health care reality. The above analysis
implicitly assumes that all mothers receive care by the twelfth week
of gestation for monthly checkups and adhere to the advice of their
primary care providers in decisions regarding the management of
pregnancy. In actuality, this scenario is unlikely. Lower-income
mothers may lack the resources to travel to monthly checkups or
may be discouraged from visits by a lack of health insurance or poor
access to, or poor treatment in, public facilities. This study viewed
all costs from a societal perspective and thus abstracted from the
incidence of test and treatment costs. Even if the costs are covered
by insurance, mothers without insurance will have a disincentive to
report for pregnancy checkups. If this is the case, the benefits to be
derived from screening for congenital toxoplasmosis will not be
evenly distributed across income strata and demographics, and
societal benefits are correspondingly reduced as well. This analysis
assumes that initiating best practice is an essential step to promoting
adherenceandwillcontribute tothe momentumforuniversalaccess
to health care, in particular adequate prenatal care, which provides
other benefits to society as well.
Adherence can also be impaired due to maternal preference,
regardless of income or accessibility. In France, in spite of
compulsory universal screening, public medical care was associ-
ated with a late first test, fewer tests, and longer intervals between
tests [95]. Public health coverage in the United States would need
to address those shortcomings to achieve universal screening.
Policy makers will also have to consider not only the extent to
which screening may be cost saving, but also the important
question of ‘‘who pays?’’ Taxpayers will likely bear the burden of
test and treatment costs for low-income mothers.
A further consideration is necessitated by the potentially low
positive predictive value of maternal serum tests. If specificity
Figure 5. Sensitivity analysis of incidence of primary T. gondii infection during pregnancy.
doi:10.1371/journal.pntd.0001333.g005
Figure 6. Sensitivity analysis of incidence of primary T. gondii infection during pregnancy (detail).
doi:10.1371/journal.pntd.0001333.g006
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prevalence of congenital infection dominates the calculation of
positive predictive value, resulting in tests for which as few as 20%
of positive test results correspond to actual infection.
The present study is based on the assumption of 100%
specificity after confirmatory test at a high quality reference lab. A
study sponsored by the US Centers for Disease Control and
Prevention (CDC) compared six test kits available for the detection
of T. gondii antibodies in serum and found the sensitivity of the tests
that might be used for screening ranged from 93.3% to 100% and
the specificity ranged from 77.5% to 99.1% [96]. A more recent
study compared the performance of four different Toxoplasma IgG
and IgM assays. The Toxo assays considered were Vidia Toxo IgG
and IgM (bioMerieux, Marcy l’Etoile,France), VidasToxo IgG and
IgM (bioMerieux), AxSYM Toxo IgG and IgM (Abbot Laborato-
ries, Abbot Park, IL), and Liaison Toxo IgG and IgM (Dia-Soring,
Saluggia, Italy). For the Toxoplasma IgG assays, sensitivity was 100%
and specificity between 98.49% and 100%. The Toxoplasma IgM
assays performed with sensitivity between 82.35% and 100% and
specificity between 99.73% and 100% [97].
For diseases with very low prevalence, even very high (but less
than 100%) specificity translates into low positive predictive value
(PPV), which is the probability that disease is truly present given
that the result of the screening test is positive. Written Pr(D+|T+),
it is the posterior probability of a true-positive test result.
Mittendorf and colleagues demonstrate clearly the effect of less
than 100% specificity on PPV and argue that routine screening for
toxoplasmosis in the United States is unwarranted because of the
low incidence of congenital infection. Furthermore, due to the
calculated low positive predictive value of serology tests for
toxoplasmosis, they estimated that 12.1 fetuses without CT would
be aborted for every fetus detected with congenital toxoplasmosis
[98]. Given these calculations, they concluded that the adverse
effects for healthy fetuses of universal screening outweigh the
benefits derived from early detection and treatment of infected
fetuses.
The implications of the Mittendorf et al. analysis were
considered very carefully. There are two reasons that their
analysis does not apply. First, the protocol herein requires a
confirmatory test at a reference lab, which at the present time has
Figure 7. Sensitivity analysis on T. gondii seroprevalence.
doi:10.1371/journal.pntd.0001333.g007
Figure 8. Sensitivity analysis on serologic test costs.
doi:10.1371/journal.pntd.0001333.g008
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best practice. Mittendorf and colleagues and others using their
analysis postulate elected abortions upon a positive confirmatory
test [64,98,99]. CT is a treatable condition in almost all cases and
thus, treatment, not abortion, is almost always considered best
practice. Therefore, our model calculates the cost savings without
assuming elected abortions. In recent years in France, there have
been so few elected terminations (three reported in 2008) [9,17]
that including estimates would not alter our results. For infected
mothers, the adverse consequences of universal screening can be
reduced through the use of further confirmatory testing, such as
amniocentesis with PCR. A recent study of the use of PCR of
amniotic fluid in France reported a specificity of 100%, sensitivity
of 92%, and positive predictive value of 100% [14,73], meaning
that a positive result definitively identifies infection of the fetus
[73].
The use of amniocentesis to confirm fetal infection (positive
predictive value of 100%) can reduce the risk of misinformed
abortion, but this potentiality hinges on proper education of
primarycare physiciansandmothers.Thepotentialproblemsposed
by positive predictive value are not devastating to the implemen-
tation of a screening program, although they do urge caution and
diligence in the implementation of any such programs.
While the use of PCR of amniotic fluid may prevent
unnecessary elected abortions of healthy fetuses, sampling
amniotic fluid is an invasive procedure and itself carries a risk of
fetal loss. In the 1970s, the risk of miscarriage due to amniocentesis
was estimated to be 0.50% (1 in 200) [91]; but in that era
continuous ultrasound guidance for the procedure was not routine,
and clarity and quality were far inferior to that of ultrasonography
today. Amniocentesis is now considered routine, where medically
indicated, and recent studies suggest a far lower rate of fetal loss
due to amniocentesis; the Mayo Clinic reports loss rates of 1 in 300
(0.33%) to 1 in 500 (0.20%), and a recent study suggests far lower
loss rates of 1 in 1,600 (0.06%) [90,92]. We use an average of the
two Mayo Clinic estimates in the model (0.25%), which may
greatly overstate risk.
A concern with adding any testing to a prenatal protocol is the
additional anxiety for mothers. Serology for T. gondii, however, can
be carried out along with other routine tests and need not impose
unusual stress. Moreover, mothers need not be informed of
suspicious results until the sample has been confirmed with a
Figure 9. Two-way sensitivity analysis on incidence of primary T. gondii infection during pregnancy and serologic test costs.
doi:10.1371/journal.pntd.0001333.g009
Figure 10. Two-way sensitivity analysis on incidence of primary T. gondii infection during pregnancy and serologic test costs
(detail).
doi:10.1371/journal.pntd.0001333.g010
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lab. Thus only true positives would be informed of the need for
medication and amniocentesis. Certainly, those both generate
concern and risk. Except in extreme cases, however, mothers are
not anxious about impossible outcomes, but about real outcomes,
albeit having low probability in most cases. Awareness of personal
agency is a powerful antidote to anxiety. Knowledge that they can
help their unborn children with better information would be more
likely to alleviate maternal anxiety than to make it less bearable.
An additional limitation of the model is that only two possible
strategies were analyzed: no screening and prenatal screening and
treatment. Pre-pregnancy education was incorporated into the
model via sensitivity analysis of reduction in seroprevalence and
primary infection during pregnancy to assess the impact of the
efficacy of education on the decision. Reducing the rate of
maternal and congenital infection by as much as 60% (the
suggested effect of maternal education) reduces the extent to which
screening is cost saving, although, even with that effect, subsequent
screening remained the optimal strategy. Recent analyses indicate
that many times risk factors for T. gondii infection go unrecognized
and thus could not be eliminated by education alone [29,59,100].
Additionally, universal neonatal screening was not considered in
the model. Incorporation of this third strategy could render
prenatal screening a sub-optimal strategy if cost is the only
consideration, although screening would still be cost saving when
compared to no systematic screening and no screening at all.
Neonatal screening, however, misses the opportunity to treat
prenatally and prevent profound injury with life-long consequenc-
es for the child, the family, and society.
Finally, sensitivity analysis on the efficacy of treatment was not
performed. Treatment efficacy estimates were generated based on
published clinical results, and thus have not been subjected to
sensitivity analysis, although variation of these estimates could
have a potentially significant effect on the results generated by the
model. More extensive screening and treatment in the United
States would contribute to knowledge of efficacy in this
population, with its possible mixture of European and Western
Hemisphere strains of T. gondii, although preliminary results
suggest that treatment is equally efficacious for different strains
[94]. Moreover, if congenital toxoplasmosis becomes a more
widely understood and reported disease in the United States,
estimates of the rate of congenital infection will become more
accurate and region-specific. A protocol of screening in suspected
high-incidence populations would be another alternative.
Conclusion
Universal screening according to the French protocol is cost
saving for the US population within broad parameters for costs,
seroprevalence, incidence of maternal and congenital toxoplas-
mosis, value of statistical life, and risk of fetal death from
amniocentesis. It is also robust to changes in the discount rate
within the normal range for health interventions.
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